Assessment of Therapeutic Potential of Stigma Maydis (Cornsilk) on Metabolic Syndrome

NCT06240273 | Unknown DMC

• 1 other identifier: Silk syndrome
• Study Type: interventional
• Target: 50
• Locations: 0 countries
• Sites: N/A

Brief Summary

Over the past two decades, there has been an increase in the number of people with nutrition related maladies due to changes in their dietary habits and lifestyle. Cardiovascular disease, type 2 diabetes, metabolic syndrome, obesity, and cancer have emerged as prominent contributors to both illness and death, particularly as the population continues to age. The mortality figures for cardiovascular disease and diabetes varied between 179.8 to 765.2 per 100,000 individuals, with the most elevated rates observed in poor nations. The occurrence of metabolic syndrome was markedly prevalent, spanning from 19% to 45%. The incidence of overweight and obesity (defined by a body mass index ≥25 kg/m2) has surged to concerning levels across many countries in the region, ranging from 25% to 82%, with a higher occurrence among women. Due to side effects of allopathic treatments and increase in nutrition knowledge people are more inclined to natural therapies. Subsequently, corn silk with nutraceutical properties may provide an effective alternative therapy to alleviate symptoms and decrease healthcare loss. Cornsilk, the often-overlooked byproduct of maize cultivation, is rich in bioactive compounds, including flavonoids, polysaccharides, and vitamins, cornsilk has shown promising effects in promoting health and wellness.

Conditions

Metabolic Syndrome

Keywords

Metabolic Syndrome; Hypertension; Obesity; Insulin Resistance; Diabetes; Cornsilk powder; Dyslipidemia

Outcome Measures

Primary Outcomes (4)

• Lipid profile will be assessed before and after the trial.

  The change in lipid profile, after 45 days intervention of corn silk extract, will be assessed. The value will be closed to optimized values.

  45 days

• waist circumference will be measured before and after the trial.

  the change in weight will be measured after 45 days of corn silk extract intervention. The value will be close to normal ranges.

  45 days

• Blood pressure will be assessed before and after the trial.

  The change in systolic and diastolic blood pressure will be measured after 45 days intervention of corn silk extract. The values will become close to optimized levels.

  45 days

• Fasting glucose level will be assessed before and after the trial.

  The change in fasting glucose levels will be assessed after 45 days intervention of corn silk extract powder. The values will be become close to optimized levels

  45 days

Study Arms (1)

Metabolic Syndrome patients

EXPERIMENTAL

Cornsilk (Stigma maydis) is used for preventing symptoms of metabolic syndrome patients Dietary Intervention: Cornsilk Extract Dosage: 2g/day

Dietary Supplement: Corn silk powder

Interventions

Corn silk powder DIETARY_SUPPLEMENT

Corn silk (CS) is abundant in phenolic compounds, especially flavonoids. It also contains proteins, vitamins, carbohydrates, calcium, potassium, magnesium, sodium salts, volatile oils, sterols like sitosterol and stigmasterol, alkaloids, and saponins. Numerous studies have explored the pharmacological activities associated with CS.

Also known as: stigma maydis

Metabolic Syndrome patients

Eligibility Criteria

• Age: 35 Years - 50 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Waist Circumference of ≥40 inches in males and ≥35 inches for females
• Subjects having fasting total cholesterol level of ≥ 200 mg/dl or LDL cholesterol ≥ 130 mg/dl.
• Fasting Blood Glucose ≥110mg/dl.
• SBP ≥ 130/ ≥ 85 mmHg

You may not qualify if:

• Participants aged 55 or above • Participants who have less than two risk factors

Sponsors & Collaborators

• University of Veterinary and Animal Sciences, Lahore - Pakistan: lead

Related Publications (2)

• Shahzad MK, Amir Shahzad M, Qadeer U, Mehmood A. Investigation of phytochemical profiling and therapeutic effects of corn silk against diabetes in human male subjects. Pak J Pharm Sci. 2022 Nov;35(6(Special)):1699-1703.

  PMID: 36861231 BACKGROUND

• Shi S, Yu B, Li W, Shan J, Ma T. Corn silk decoction for blood lipid in patients with angina pectoris: A systematic review and meta-analysis. Phytother Res. 2019 Nov;33(11):2862-2869. doi: 10.1002/ptr.6474. Epub 2019 Aug 18.

  PMID: 31423665 BACKGROUND

MeSH Terms

Conditions

Metabolic Syndrome; Hypertension; Obesity; Insulin Resistance; Diabetes Mellitus; Dyslipidemias

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Vascular Diseases; Cardiovascular Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Endocrine System Diseases; Lipid Metabolism Disorders

Study Officials

• Dr. M. Asif Ali, PhD

  University of Veterinary and Animal Sciences, lahore

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Rija Jafar, Mphil

CONTACT

0302-4586616; rijajafar@gmail.com

Dr. M. Asif Ali, PhD

CONTACT

042-99211374; asif.ali@uvas.edu.pk

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: None (open-label) Participants Groups
• Purpose: SUPPORTIVE CARE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Single group Assignment Case-control Study

Study Record Dates

• First Submitted: January 17, 2024
• First Posted: February 5, 2024
• Study Start: February 20, 2024
• Primary Completion: April 20, 2024
• Study Completion: May 20, 2024
• Last Updated: February 5, 2024

Record last verified: 2024-01

Data Sharing

• IPD Sharing: Will not share